Federal Regulators — Closed-Door Industry Meetings on Clinical AI (2026 Update)
OVERVIEWReports indicate that FDA and CMS officials have held closed-door meetings with healthcare AI industry representatives to informally discuss regulatory approaches and approval pathways. These meetings occur outside public comment processes, raising transparency concerns about industry influence over regulatory development. The meetings reportedly focus on resolving conflicts between state-led AI sandboxes and federal oversight, clarifying the TEMPO pilot program, and establishing clearer pre-market validation standards. While informal coordination can be efficient, the closed-door nature limits public input and creates appearance of regulatory capture. Healthcare advocates have called for more transparent regulatory development processes that include patient representatives, clinician input, and public stakeholder comment. --- CONTRADICTIONS
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.